Follicle center lymphoma (FCL) is an indolent low-grade B cell non-Hodgkin's lymphoma (NHL) that frequently transforms to aggressive diffuse large B cell lymphoma (DLBCL). Histological transformation of FCL is commonly associated with accumulation of secondary genetic alterations. The BCL-6 gene is commonly implicated in the pathogenesis of DLBCL and its expression may be altered by clonal rearrangements and somatic point mutations in its 5Ј non-translated regulatory region. Recently, somatic mutations of the BCL-6 gene were associated with the transformation process. Here, we examined BCL-6 mRNA expression and BCL-6 mutations in paired biopsies from the same patients obtained at the time of FCL diagnosis and after transformation. BCL-6 mRNA expression markedly increased upon transformation (1.9-to 4.8-fold) in three cases, remained unchanged in one case and decreased compared to the diagnosis FCL specimens in four cases. The three specimens that demonstrated an increase in the BCL-6 mRNA expression upon transformation harbored BCL-6 gene mutations in the 5Ј region of the first intron that overlapped with the previously reported negative regulatory region of the gene. Accumulation of new mutations in this region was not observed in DLBCL biopsies in which the BCL-6 mRNA expression did not increase. The present study demonstrates that although BCL-6 gene mutations do accumulate during the transformation process and, depending on their location within the first intron, may deregulate BCL-6 mRNA expression, increase in BCL-6 mRNA expression is not uniformly required for transformation from FCL to DLBCL.
Introduction
Follicle center lymphoma (FCL) is a low-grade non-Hodgkin's lymphomas (NHL) characterized by long survival and a relatively indolent clinical course. Nonetheless, transformation to a higher grade aggressive lymphoma occurs in 25-60% of patients. 1, 2 The transformation is usually associated with a rapidly progressive clinical course and short survival. The molecular mechanisms underlying the process of morphologic transformation and clinical progression of FCL are presently unknown, however their identification is critical for the improved understanding of the pathogenesis of these lymphomas. Secondary genetic abnormalities associated with histological transformation of FCL include genome wide genetic instability, 3 nonrandom chromosomal changes, [4] [5] [6] c-myc gene rearrangement, 7, 8 p53 tumor suppressor gene mutations, 9, 10 p16 and p15 inactivation by deletions, mutations and hypermethylation 11, 12 and somatic mutations of the translocated BCL-2 gene. 13 However, these secondary aberrations are markedly heterogeneous and are each observed in only a subset of transformed lymphomas, suggesting that other molecu- Recently, we and others described the accumulation of somatic mutations in the 5Ј non-translated regulatory region of the BCL-6 gene during transformation. [14] [15] [16] The BCL-6 gene is located at chromosome 3q27 and encodes a 96KD nuclear protein with six C-terminal zinc finger motifs and an N-terminal POZ/ZIN domain homologous to a family of zinc finger proteins. 17 This gene is commonly implicated in the pathogenesis of diffuse large B cell lymphomas (DLBCL) and its expression may be altered by clonal rearrangements and somatic point mutations of its 5Ј nontranslated regulatory region. [18] [19] [20] [21] [22] [23] [24] However, only 33% of the mutant alleles found in primary DLBCL caused BCL-6 overexpression. 25 The nature of the somatic mutations leading to the changes in the BCL-6 expression has not been reported in this abstract. 25 Consequently, the observed accumulation of the somatic mutations in the 5Ј non-translated regulatory region of the BCL-6 gene during higher grade transformation of FCL to DLBCL may play a functional role in the process of transformation. We have now examined and correlated BCL-6 mRNA expression and somatic mutations in the 5Ј nontranslated regulatory region of the BCL-6 gene in sequential biopsy specimens from FCL patients that underwent morphologic transformation to DLBCL.
Materials and methods

Tumor specimens
Sequential biopsy specimens from eight patients with FCL that underwent morphologic transformation to DLBCL were selected for this study. All lymphoma specimens were classified according to the Revised European-American Lymphoma Classification 26 (Table 1) and were routinely immunophenotyped by flow cytometry for expression of immunoglobulin (Ig) heavy and light chains and B and T cell markers. Percentage of the tumor cells in each specimen was estimated from the light chain restriction in each specimen as determined by flow cytometry (goat F(abЈ) 2 FITC anti-human and antibodies; Biosource International, Camarillo, CA, USA). Lymph node histology at the time of transformation was classified as DLBCL in all the specimens. In three cases (IL105B, IL114C and IL119B) no remaining follicles were observed while in the other transformed cases some remaining scattered follicles were seen in addition to the classical DLBCL pathological findings.
RNA isolation and real-time PCR measurement of the BCL-6 mRNA expression
Total cellular RNA was isolated using the RNeasy kit (Qiagen, Valencia, CA, USA) according to the manufacturer's instruc- tions. BCL-6 mRNA expression was measured by real-time quantitative reverse transcription (RT)-PCR using the TaqMan technology on an ABI Prism 7700 Sequence Detection System (PE Applied Biosystems, Foster City, CA, USA) as was previously reported. 27 For each reaction 20 ng of total RNA were used. Since the precise amount of total RNA added to each reaction mix and its quality (ie extent of RNA degradation) are both difficult to assess, we also quantified the level of glyceraldehyde -3-phosphate dehydrogenase (GAPDH) as the endogenous RNA control, and each sample was normalized on the basis of its GAPDH content. To allow the relative expression of BCL-6 gene to be compared across all the tested samples, the sample BCL-6/GAPDH expression was also normalized to the BCL-6/GAPDH values concomitantly measured in Raji cells (calibrator) as suggested in ABI 7700 user Bulletin 2 (PE Applied Biosystems) and previously reported. Each RT-PCR run included the five points of the calibration curve for BCL-6 and GAPDH (five-fold diluted human RNA), a no-template control, the calibrator Raji RNA and patient's samples, all in triplicates.
Identification of the BCL-6 gene mutations
High molecular weight DNA was extracted from 5.0 × 10 6 cells using a commercially available kit as described by the manufacturer (QIAamp Tissue Kit; Qiagen). The first intron region of the BCL-6 gene, that has previously been shown to contain more than 90% of the BCL-6 gene mutation in B cells, 21 was amplified by PCR using 5Ј-CCGCTGCTCATGAT-CATTATTT and 5Ј-TAGACACGATACTTCATCTCAT primers, as was previously reported. 24 The first exon region of the BCL-6 gene, that has previously been shown to contain less than 10% of the BCL-6 gene mutation 21 was amplified by PCR using 5Ј-ACGCTCTGCTTATGAGGA and 5Ј-CGGCAGCAA-CAGCAATAA primers.
For each PCR, a control with no added template was used to check for contamination. PCR products were analyzed by 2% agarose gel electrophoresis and staining with ethidium bromide. Bands of appropriate size were excised from the gels and purified by adsorption to a silica matrix (QIAquick columns; Qiagen). The PCR products were cloned and sequenced as previously reported. 24 Briefly, the purified PCR amplicons were ligated into a TA-PCR cloning vector (Invitrogen, Carlsbad, CA, USA), and were used for transformation of competent Escherichia coli (One Shot INV ␣FЈ, Invitrogen) according to the manufacturer's instructions. Twelve to 24 white colonies were picked per sample and used in a second round of PCR. All the PCR amplicons (range, [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] were sequenced on a 373 automatic DNA sequencer (Applied Biosystems) using ABI Prism Big Dye Terminator Kit (Perkin Elmer) as recommended by the manufacturer. The same primers used for the PCR were used for forward and backward sequencing.
Sequence analysis was done using the MacVector program (Oxford Molecular Group, Campbell, CA, USA). Sequences were aligned with the BCL-6 first exon and the BCL-6 first intron hypermutation region germ line (Gene Bank accession numbers Z79581 28 and AF 191831, 24 respectively) and were analyzed according to previously reported criteria and definitions. 14, 24 The mutations were defined as follows: unconfirmed mutation -a substitution mutation observed in only one of the BCL-6 gene clones from the same tumor specimen; confirmed mutation -a mutation observed more than once in the BCL-6 gene clones from the same tumor specimen. The Taq polymerase error frequency in our laboratory is 0.09%, which may amount to 0.71 mutations/BCL-6 clone. Since single unconfirmed mutations observed in only one molecular clone should not significantly affect tumor BCL-6 mRNA expression and since some of them could have resulted from Taq polymerase error, the unconfirmed mutations were disregarded. The first nucleotide of the amplified BCL-6 first intron gene region, corresponding to the first nucleotide of the sense primer was arbitrarily defined as position +1. Tumor mutation status was determined disregarding previously established polymorphisms. 21, 24 Presence of the polymorphisms or the pattern of mutations allowed assignment of the two alleles of the tumor and determination of ongoing mutations. Mutational analysis of the BCL-6 first intron region of all but specimens IL123A, IL123B, IL123C, IL126A and IL126B were reported in our previous study.
14 Two specimens analyzed in our previous study 14 were not included in the present study because of insufficient number of cells for RNA preparation.
Leukemia
Immunohistochemistry
Paraffin blocks from both pre-and post-transformation biopsies were available for six of the study patients. A primary antibody directed against BCL-6 (Courtesy of Dr Brunangelo Falini, Department of Hematology, Perugia University, Italy 29, 30 ), was used for immunohistochemical staining. Serial sections of 4 microns were cut from paraffin blocks and deparaffinized in xylene and hydrated in a graded series of alcohol solutions. This was followed by heat-induced antigen retrieval carried out by microwave pretreatment in EDTA (1 mM, pH 8.0) for 15 min prior to staining. Endogenous peroxidase was blocked by pre-incubation with 1% hydrogen peroxide in phosphate-buffered saline. Staining detection was carried out using a modified biotin-streptavidin-horseradish peroxidase method. 31 Staining for BCL-6 was localized predominantly to the nucleus. Percentage of malignant cells stained with BCL-6 was estimated based on cell morphology. Interpretation of the immunostaining was performed without knowledge of the real-time RT-PCR results.
Statistical analysis
A correlation between BCL-6 mRNA expression and the location of new BCL-6 gene mutation (excluding ongoing mutations present in some but not all the clones derived from the same allele) was performed by Fisher exact test.
Results
We measured BCL-6 mRNA expression by real-time quantitative RT-PCR (Figure 1 ). In addition, we determined the BCL-6 gene first intron mutations by cloning and sequencing. Sequential biopsies were analyzed from the time of FCL diagnosis and transformation to DLBCL in eight patients. Clonal relationship between the members of each pair of tumors was confirmed by examination of immunoglobulin genes in all the cases except case IL119 in which it was not performed (data not shown).
BCL-6 mRNA expression markedly increased (1.9-to 4.8-fold) in three post-transformation DLBCL specimens (IL116, IL120 and IL126), remained almost unchanged in one DLBCL specimen (IL105) and decreased compared to the diagnosis FCL specimens in four post-transformation DLBCL biopsies ( Table 1 ). The observed alterations in the BCL-6 mRNA expression could not be attributed to a change in the number of tumor cells in the specimens. In the three cases that demonstrated a 1.9-, 4.3-and 4.8-fold increase in the BCL-6 mRNA expression, the tumor cell percentage in the specimens, as determined by FACS analysis, increased from 69% to 82% (1.2-fold increase), decreased from 68% to 43% and did not changed (68% and 71%), respectively. The absence of consistent increase in the BCL-6 mRNA expression in all the posttransformation specimens demonstrate that increase in BCL-6 mRNA expression is not necessary for FCL transformation to DLBCL. BCL-6 protein immunohistochemistry staining was performed in six-paired biopsies. No correlation was observed between the quantitative BCL-6 mRNA expression measurement and the estimation of the BCL-6 stained malignant cells. Absence of concordance between BCL-6 mRNA and protein expression has been previously reported, 27 ,32 most probably due to existence of post-transcriptional regulatory mechanisms 33 and due to the fact that number of BCL-6-positive cells does not account for quantitative protein expression in each cell.
It is known that some BCL-6 gene mutations in the 5Ј noncoding regulatory region may deregulate BCL-6 gene expression. 21, 25 Therefore, we examined the transformed lymphomas for mutations in the regulatory region of their BCL-6 gene. New BCL-6 gene mutations that accumulated during FCL transformation to DLBCL were detected in four of the eight post-transformation DLBCL specimens. In two of these cases accumulation of new mutations was associated with an increase in the BCL-6 mRNA expression. In an additional posttransformation specimen (IL126B), in which BCL-6 mRNA expression increased, new mutations associated with the transformation were not detected, however, the number of molecular clones harboring mutations 84(GϾA), 104(AϾC) and 153(TϾG) increased in the DLBCL specimen, most probably reflecting clonal selection. In this case a 1.6-fold increase in the prevalence of clones derived from the same allele (based on a polymorphism present in this case) that harbored these ongoing mutations in the DLBCL specimen was associated with a 1.9-fold increase in the BCL-6 mRNA thus suggesting higher BCL-6 expression in cells with BCL-6 mutations. Our findings show that neither accumulation of new BCL-6 gene mutations nor an increase in the BCL-6 mRNA expression are necessary for FCL transformation to DLBCL. Clonal selection was also observed in cases IL119, IL120 and IL123. In cases IL119 and IL123 it was characterized by a loss of a clone with BCL-6 gene mutations and in neither of these two cases did BCL-6 mRNA expression increase upon transformation. In the IL120 case, clonal selection was associated with acquisition of new BCL-6 gene mutations and an increase in the BCL-6 mRNA expression.
Specimens with increased BCL-6 mRNA expression harbored mutations that clustered in the 5Ј region of the BCL-6 gene first intron (84(GϾA), 88(GϾC), 104(AϾC), 153(TϾG) and 180(TϾA)), while specimens in which no increase in the BCL-6 mRNA expression was observed harbored mutations that clustered in the more distal part of this intron (the only exception was mutation 182(TϾG) in specimen IL114C; however, this mutation was a manifestation of intraclonal heterogeneity and was observed in only 23% of the evaluated molecular clones). Mutation 104 (AϾC) was shared by two of the three DLBCL cases in which BCL-6 mRNA expression increased upon transformation.
The distribution of these 5Ј proximal new mutations observed in specimens in which an increase in the BCL-6 mRNA expression was observed, almost perfectly overlapped with the recently discovered negative regulatory region within the first intron of the BCL-6 gene (nucleotide positions 97-232) (Figure 2 ), whose exact boundaries were not extensively investigated. 34 A correlation existed between the increase in the BCL-6 mRNA expression and the clustering of mutations in or nearby the discovered negative regulatory region within the first intron of the BCL-6 gene (P Ͻ 0.02, by Fisher exact test). Thus mutations in this region may interfere with the negative regulatory function of this region and lead to an increase in the BCL-6 mRNA expression, as was observed in the three post-transformation DLBCL cases. In contrast, none of the new mutations, observed in the majority of molecular clones and located 3Ј to this region, were associated with an increase in the BCL-6 mRNA expression in the transformed specimens thus suggesting that they are functionally insignificant. Kikuchi et al 34 also reported on the existence of an additional negative regulatory region located in the 3Ј part of the BCL-6 first non-translated exon. Sequencing of this region in the IL116A, IL116B, IL120A, Il120B, Il126A and IL126B specimens, in which BCL-6 mRNA expression increased upon transformation to DLBCL disclosed germ line sequences and no new mutations acquired during transformation were detected.
Figure 2
Schematic representation of the distribution of BCL-6 gene mutations associated with FCL transformation. New mutations are in red, new ongoing mutations present in some but not all the molecular clones derived from the same allele are in green and mutations representing clonal selection upon transformation are in blue.
Discussion
Following recent reports that FCL transformation to DLBCL is associated with an accumulation of mutations in the 5Ј nontranslated regulatory region of the BCL-6 gene [14] [15] [16] and previous reports that some BCL-6 gene mutations may deregulate its expression, 25 we examined the functional significance of these mutations and the possible role of the BCL-6 gene expression in the process of FCL transformation to DLBCL. Our findings indicate that an increase in the BCL-6 mRNA expression is not necessary for the histological transformation of FCL to DLBCL. Transformation to DLBCL was associated with an increase in the expression of the BCL-6 mRNA in only three out of the eight evaluated case, while in the remaining five cases BCL-6 mRNA expression did not changed or decreased upon higher grade transformation. BCL-6 mRNA expression did not change or slightly decreased in FCL relapse specimens (data not shown).
In addition, we have correlated the data on the accumulation of new BCL-6 gene mutations in sequential biopsy specimens to the levels of the BCL-6 mRNA expression. The use of real-time quantitative RT-PCR, rather than reporter gene assays, allows examination of the endogenous gene expression status and takes into account any possible interactions between the two BCL-6 gene alleles. The analysis suggests that the location and perhaps the nature of the mutations may determine their effect on the BCL-6 mRNA expression. Kikuchi et al recently demonstrated the presence of negative regulatory regions within the first non-translated exon and in the 5Ј portion of the first intron of the BCL-6 gene. 34 In our analysis mutations were associated with an increase in the BCL-6 mRNA expression when they occurred in the 5Ј portion of the first intron of the BCL-6 gene at positions almost perfectly overlapping with the reported negative regulatory region whereas mutations were not associated with an elevated BCL-6 mRNA expression if they occurred 3Ј to this region. No mutations were observed in the first non-translated exon of the BCL-6 gene in the specimens obtained from three cases that demonstrated an increase of the BCL-6 mRNA expression upon transformation. Recently, Pasqualucci et al 25 reported the effect of the BCL-6 gene mutations on reporter gene expression in 11 lymphoma cases (six primary DLBCL and five Burkitt lymphomas (BL), corresponding to 20 mutated alleles) and normal germinal center (GC) cells (20 mutated alleles). Significant over-expression of the reporter gene was observed in only 33% of DLBCL mutant alleles derived from three out of six DLBCL cases. The nature and the location of the mutations in the alleles affecting the reporter gene expression were not reported. 25 Overall, the data suggest that some BCL-6 gene mutations may have functional significance while others do not. Consecutively, some BCL-6 gene mutations that accumulate during the process of FCL transformation to DLBCL may up-regulate BCL-6 mRNA expression while others do not affect its expression.
In our previous study using cDNA microarrays we demonstrated that the differentiation stage of the B cell lymphocyte at which DLBCL originates is important in determination of the clinical aggressiveness of the tumor and of patient survival. 35 Thus germinal center (GC) -like DLBCL had a better outcome than activated peripheral B cell -like DLBCL. Recently, we have demonstrated that BCL-6 mRNA expression assessed by real-time quantitative RT-PCR may also be useful in defining the two groups of primary DLBCL with different survival. 27 Primary DLBCL with high BCL-6 gene expression (defined as more than 1.3-fold over normalized BCL-6
Leukemia expression in Raji cells) had significantly better survival than primary DLBCL with BCL-6 mRNA expression lower than 1.3-fold. All the transformed DLBCL specimens analyzed in the current study expressed BCL-6 mRNA at levels higher than 1.3-fold thus suggesting their GC origin. This observation suggests that the origin of transformed DLBCL, similar to the origin of the preceding FCL, is from GC lymphocytes. However, the reason for different clinical behavior of primary DLBCL origination from GC lymphocytes and transformed DLBCL also originating from the same cells is presently unknown.
In summary, we have demonstrated that although BCL-6 gene mutations accumulate during the process of FCL transformation to DLBCL and some of them may deregulate BCL-6 mRNA expression, the increase in BCL-6 mRNA expression is not uniformly necessary for the transformation process. The molecular mechanisms involved in the transformation of FCL to DLBCL remain to be elucidated.
Editorial note
In the present report the authors clearly demonstrate absence of concordance between BCL6 mRNA and protein expression in the cases investigated. This lack of correlation between transcript and protein level of BCL6 is in agreement with previous studies quoted by the authors but it is strongly contrasting the widespread prejudice assuming mRNA expression of a certain gene to reflect abundance of the encoded protein. Also, in human tissues a poor correlation (r Ͻ 0.5) between transcript and protein level has been shown. These disparities between mRNA and protein abundances suggest the importance of translational and post-translational cellular control mechanisms. In the light of the increasing importance of gene and protein expression patterns for diagnosis and prognosis of hematologic and other neoplasms a proper characterization of the interrelation between DNA, transcript and protein level has to be attempted. Therefore, the parallel investigation of normal and tumor tissues with regard to genomic alterations, transcript and protein abundances is highly encouraged as is the publication of both positive and negative correlations.
